Sakar Healthcare Ltd has been added as a contract manufacturer for Accord Healthcare UK's finished product Imatinib Accord, expected to positively impact top-line sales through expanded generic oncology offerings amid rising global demand.
Contract Expansion
This partnership leverages Sakar Healthcare's expertise in API and finished dosage formulations, focusing on Imatinib—a key generic for chronic myeloid leukemia treatment. The addition strengthens Sakar's position in the competitive generics market, particularly for export to Europe.
Key Highlights
-
Product Focus: Manufacturing Imatinib Accord finished formulations; aligns with Sakar's oncology portfolio strengths.
-
Revenue Impact: Positive top-line contribution via volume-based contract; supports FY26 growth targets amid 15% generics export surge.
-
Strategic Fit: Enhances UK/EU supply chain post-Brexit; Accord (Intas Group subsidiary) gains reliable Indian capacity.
-
Market Context: Imatinib generics market at $2 bn globally; pricing pressures favor efficient CMOs like Sakar.
Growth Trajectory
This deal signals Sakar's pivot to high-margin CDMO services, eyeing 20% EBITDA uplift with capacity expansions underway.
Sources: BSE Announcements, Economic Times Pharma Updates, Moneycontrol Corporate Filings.